Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane.
Eriseld KrasniqiGiacomo BarchiesiMarco MazzottaLaura PizzutiAlice VillaMaddalena BarbaPatrizia ViciPublished in: Medicine (2020)
Eve plus Exe remains a valid option in HR+HER2- MBC.